CBAY

Cymabay Therapeutics
CBAY

Overview Fund Activity
Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

26 hedge funds and large institutions have $74.3M invested in Cymabay Therapeutics in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.

Holders
26
Holders Change
+9
Holders Change %
+52.94%
% of All Funds
0.69%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.03%
New
12
Increased
5
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
EAM
1
EverPoint Asset Management
Connecticut
$7.35M
2
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$5.61M
3
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$3.51M
4
VAM
4
Visium Asset Management
New York
$3.33M
5
LOAMU
5
Lombard Odier Asset Management (USA)
New York
$13.5M

Top Sellers

1
DM
1
Deerfield Management
New York
$0
2
RSCM
2
Rock Springs Capital Management
Maryland
$983K
3
SFM
3
Sphera Funds Management
Israel
$3.84M
4
Jennison Associates
4
Jennison Associates
New York
$9.77M
5
Barclays
5
Barclays
United Kingdom
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Manulife (Manufacturers Life Insurance)
26
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3 +$3 +257 New
DM
27
Deerfield Management
New York
– -$3.51M -513,206 Closed
Barclays
28
Barclays
United Kingdom
– -$14K -2,400 Closed
CWAM
29
Columbia Wanger Asset Management
Illinois
– -$2K -228 Closed
1
2